The Biopark, The BioPark, Broadwater Road, Welwyn Garden City, Hertfordshire, AL7 3AX, UK
2010-03-12
9:00 – 9:45 Registration 9:45 – 9:55 Introduction by the Chair: Dr Eleanor Berrie, Clinical BioManufacturing Facility, University of Oxford, UK, 9:55 – 10:20 Overview of candidate selection, vaccine manufacturing and delivery Dr Dave Simpson, Process Development Manager, Eden Biodesign 10:20 – 10:45 A flexible Stabilisation Technology for use with Vaccines and Proteins Dr Stephen Ward, Development Director at Stabilitech, UK Improved stability against temperature excursions as applied to vaccines and biopharmaceuticals would have a significant and obvious impact upon temperature-controlled distribution. Stabilitech Ltd has overcome thermostability issues for a wide range of viruses, vaccines and biopharmaceuticals. A proprietary excipient system shall be discussed which, when mixed with suspensions of target vaccine or protein enhances the stability of the products markedly, and prevents thermal damage both when stored at elevated temperatures or during multiple freeze thaw cycles. The technology can be readily incorporated into cGMP manufacturing processes and uses standard equipment. 10:45 – 11:10 Development of a thermostable and transcutaneous adenovirus vector vaccine designed to induce broad CD8 T-cell responses to HIV Professor J George Dickson, Director Institute of Biomedical & Life Sciences, South West London Academic Network, UK Development, evaluation and optimisation of HIV-1/ SIV genetic vaccine components to generate a large pool of CD8+T cell memory cells recognising multiple CTL epitopes is currently one of the primary strategies in HIV-1/SIV vaccination protocols. We have developed systems to desiccate and store at ambient temperatures adenovirus vaccine vectors. With the aim of stimulation very broad and strong CTL responses we have developed a cohort of adeno vaccine vectors for HIV in which full-size or fragmented gag genes including cross clade conserved-epitope recombinants fused to ubiquitin sequences. Vector test outcomes are being evaluated in DC and non DC cells, in mice and in NHP models. 11:10 – 11:35 Talk to be confirmed , 11:35 – 11:40 Speakers photo 11:40 – 12:00 Mid-morning break 12:00 – 12:25 FMD vaccine development Dr David Paton, Institute for Animal Health, UK 12:25 – 12:50 Methods for delivery of GM vaccines to stimulate appropriate, protective responses Dr David JM Lewis, St George's Hospital, UK Genetic Modification offers the potential to rationally design live vaccines that are safe and effective, by attenuating harmful traits in otherwise pathogenic viruses and bacteria, making them safe for delivery to humans and animals. While live vaccines derived from pathogens offer the attractions of inducing robust cellular and humoral immunity that may be long-lasting; and immune responses in mucosal sites of colonisation or invasion; a constant issue is the balance between efficacy (immunogenicity/colonisation) and safety (reactogenicity/invasion). In addition, the use of vector organisms to carry foreign genes offers the potential for multi-valent combination vaccines in one-shot, but here the issues of level of foreign gene expression and levels of immunity induced are encountered. Finally, live vaccines must circumvent or overcome adaptive (specific) and innate (non-specific) immune and anatomical barriers before they can bring about a response. The personal clinical experience with bacterial pathogen GM vaccines gained over 6 clinical trials with Salmonella typhi, Salmonella typhimurium, Shigella dysenteriae and hybrid strains, with be reviewed to demonstrate these issues, together with practical issues of Phase 1 trial design that can influence safety and efficacy readouts. 12:50 – 14:00 Lunch and Poster Viewing 14:00 – 14:25 Can Mucosal Vaccines make Needles a Thing of the Past? Dr. Valerie Ferro, University of Strathclyde, Scotland We have developed a delivery system composed of non-ionic surfactant vesicles and bile salts (bilosomes), which protect entrapped antigen against degradation in the gastrointestinal tract. This delivery system removes the need for live or attenuated vaccines and is ideal for oral delivery of synthetic peptides and recombinant proteins. An IgA response is induced locally, while systemically the immune response can be directed towards a Th1 or Th2 bias by altering the size of the vesicles, irrespective to the pathogenic origin of the antigen. 14:25 – 14:50 Recombinant avipoxvirus vaccines Dr Michael A. Skinner, Imperial College London, Viruses of the avian poxvirus (avipoxvirus) genus represent a diverse and divergent group of poorly characterised viruses. Borrowing approaches developed for Vaccinia virus, Fowlpox virus (the type species) was developed as a live recombinant vaccine vector for use in poultry. Like the other well-known member of the genus, Canarypox virus, Fowlpox virus only causes disease in birds but it is nevertheless able to infect mammalian cells, express proteins and induce immune responses, both humoral and cellular, which may in some circumstances be protective. Blocked during morphogenesis (or before) in mammalian cells, they have extremely high safety profile as live recombinant vaccine vectors for use in humans and other mammals, as demonstrated in numerous clinical trials (recombinant Canarypox virus, used in prime-boost vaccination with recombinant protein, has recently returned the first indications of partial success in an HIV vaccine trial). Relatively low potency has been addressed by using prime-boost regimes and by co-expression of host cytokines or co-stimulators. New generation vectors may involve deletion of avipoxvirus immunomodulators to improve efficacy safely. The focus of our current work is to identify appropriate immunomodulators for deletion. 14:50 – 15:00 Oral presentation 15:00 – 15:30 Afternoon Tea/Coffee and Last Poster Viewing 15:30 – 15:40 Construction and Evaluation of Safe Live Attenuated Cholera Vaccine, VCUSM21PMurugaiah Chandrika, School of Health Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Kelantan, Malaysia 15:40– 16:05 Clinical trials of a novel influenza vaccine Sarah C. Gilbert, Reader in Vaccinology, Jenner Institute, Oxford Currently licensed influenza vaccines are designed to induce antibodies against the polymorphic external proteins of the virus, chiefly haemagglutinin. They can achieve 80% effectiveness when the vaccine strain and circulating virus are well matched, but substantially less when the circulating virus changes, and are never as effective in those aged 65. Completely new versions are required to protect against possible pandemic viruses. The Jenner Institute is testing a new type of influenza vaccine using the conserved internal proteins of the virus to boost cellular immunity to all subtypes of influenza A with a single vaccine. Cellular immunity is an important component of natural immunity to influenza virus and the clinical trials are designed to examine the safety, immunogenicity and efficacy of this new type of influenza vaccine. 16:05 - 16:30 Optimizing vaginal responses to HIV vaccines Professor Robin Shattock, St Georges University of London, UK 16:30 - 17:00 Chairman’s summing up
|